2008
DOI: 10.1007/s10549-008-9967-7
|View full text |Cite
|
Sign up to set email alerts
|

Validation of the Tenon breast cancer score for predicting non-sentinel lymph node status in breast cancer patients with sentinel lymph node metastasis: a prospective multicenter study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
25
0
12

Year Published

2008
2008
2013
2013

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 53 publications
(37 citation statements)
references
References 29 publications
0
25
0
12
Order By: Relevance
“…According to the authors, the weakness of this scoring system is that it does not take the size of nodal metastasis and extranodal dissemination into account [9]. Studies that validated the Tenon score, reported ROC values of 0.75 [17], 0.82 [24], and 0.582 [12]. The third study, which reported the lowest value, was carried out by Gur et al [12] on a Turkish patient population.…”
Section: Nomogram Resultsmentioning
confidence: 99%
“…According to the authors, the weakness of this scoring system is that it does not take the size of nodal metastasis and extranodal dissemination into account [9]. Studies that validated the Tenon score, reported ROC values of 0.75 [17], 0.82 [24], and 0.582 [12]. The third study, which reported the lowest value, was carried out by Gur et al [12] on a Turkish patient population.…”
Section: Nomogram Resultsmentioning
confidence: 99%
“…References validating a nomogram, n= 10 excluded [42][43][44][45][46][47][48][49][50][51] Potentially appropriate references to be included in review, n= 64 …”
Section: Figurementioning
confidence: 99%
“…D'autres scores ou nomogrammes ont été égale-ment publiés : le score de Tenon [13] d'utilisation simple, récemment évalué dans une série multicentrique confi rmant la reproductibilité du modèle [43] ; le modèle d'utilisation également simple du MD Anderson [108] ; le modèle simple proposé par Chagpar et al [29], avec une population dont le risque d'atteinte des GNS inférieur à 5 % reste très limité, réduisant son intérêt clinique. D'autres scores ont été rapportés, mais n'ont pas été validés de manière prospective.…”
Section: Scores Et Nomogrammesunclassified